Tom: Trim away, don't let me sway you but the cohort 3 results are fantastic. GRMD02 achieved a statistically significant reduction in alpha-2 macrogobulin from FibroTest. Alpha-2 macrogobulin correlates to the amount of liver fibrosis (as a biomarker for evidence of liver fibrosis). Individual investors/day traders do not understand the significance of this achievement. And for the stock price to move up, we require more institutional buyers. I am very optimistic regarding phase 2 and I think that it will be worth waiting for. we will either end up at zero or $100 per share. NASH with cirrhosis is a seriously unmet and urgent medical need. The only real option for treatment is liver transplant and that costs $350,000 per procedure and does not work very well and there are almost no available livers. ALL IMHO. Please make your own trading decision.
News 
Market Data 
Discover 
